Literature DB >> 34896571

Osteosarcoma from the unknown to the use of exosomes as a versatile and dynamic therapeutic approach.

Ana Santos1, Cátia Domingues2, Ivana Jarak1, Francisco Veiga3, Ana Figueiras4.   

Abstract

The most common primary malignant tumor of bone in children is osteosarcoma (OS). Nowadays, the prognosis and the introduction of chemotherapy in OS have improved survival rates of patients. Nevertheless, the results are still unsatisfactory, especially, in patients with recurrent disease or metastatic. OS chemotherapy has two main challenges related to treatment toxicity and multiple drug resistance. In this way, nanotechnology has developed nanosystems capable of releasing the drug directly at the OS cells and decreasing the drug's toxicity. Exosomes (Exo), a cell-derived nano-sized and a phospholipid vehicle, have been recognized as important drug delivery systems in several cancers. They are involved in a variety of biological processes and are an important mediator of long-distance intercellular communication. Exo can reduce inflammation and show low toxicity in healthy cells. Furthermore, the incorporation of specific proteins or peptides on the Exo surface improves their targeting capability in several clinical applications. Due to their unique structure and relevant characteristics, Exo is a promising nanocarrier for OS treatment. This review intends to describe the properties that turn Exo into an efficient, as well as safe nanovesicle for drug delivery and treatment of OS.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug delivery systems; Exosomal membrane; Exosome; Osteosarcoma; Therapeutic applications

Mesh:

Substances:

Year:  2021        PMID: 34896571     DOI: 10.1016/j.ejpb.2021.12.003

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  1 in total

Review 1.  Therapeutic Strategy of Mesenchymal-Stem-Cell-Derived Extracellular Vesicles as Regenerative Medicine.

Authors:  Yasunari Matsuzaka; Ryu Yashiro
Journal:  Int J Mol Sci       Date:  2022-06-09       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.